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Abstract Circular dichroism (CD) and Raman spectroscopy
were employed in order to locate a camptothecin (CPT)-binding
site within human serum albumin (HSA) and to identify protein
structural transformations induced by CPT binding. A com-
petitive binding of CPT and 3P-azido-3P-deoxythymidine (a
ligand occupying IIIA structural sub-domain of the protein) to
HSA does not show any competition and demonstrates that the
ligands are located in the different binding sites, whereas a HSA-
bound CPT may be replaced by warfarin, occupying IIA
structural sub-domain of the protein. Raman and CD spectra
of HSA and HSA/CPT complexes show that the CPT-binding
does not induce changes of the global protein secondary
structure. On the other hand, Raman spectra reveal pronounced
CPT-induced local structural modifications of the HSA mole-
cule, involving changes in configuration of the two disulfide bonds
and transfer of a single Trp-residue to hydrophilic environment.
These data suggest that CPT is bound in the region of inter-
domain connections within the IIA structural domain of HSA
and it induces relative movement of the protein structural
domains.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
20(S)-Camptothecin (CPT) and its derivatives, potent anti-
tumour drugs against a wide range of human tumours, exhibit
their cytotoxicity by stabilising topoisomerase (topo) I^drug^
DNA ternary complexes [1,2]. CPT contains a K-hydroxy N-
lactone ring which was found to be a principal structural
requirement for the drug biological action [3]. In whole blood
versus plasma, CPT displays enhanced stability due to drug
association with the lipid bilayers of red blood cells [4]. Hu-
man serum albumin (HSA), a vast mediator of transport and
metabolism of numerous pharmaceuticals in the blood, pref-
erentially binds the hydrolysed (carboxylate) form of the drug
with a ca. 150-fold higher a¤nity than the lactone (native)
form [5]. These interactions result in CPT opening more rap-
idly and completely in the presence of HSA. Comparison of
drug stability in both plasma and puri¢ed serum albumin
samples revealed that lactone ring opening occurred to a
much greater extent in human samples as related to other
species [6]. Moreover, serum albumins from non-human spe-
cies were found to bind CPT much weaker than HSA. Hence,
the question of interactions of CPT with blood components
and, particularly with HSA, seems to be extremely important
if the problem of drug delivery to its target is concerned.
The structural basis of CPT interactions with HSA remains
to be de¢ned. It was noted [4] that crystallographic analysis of
CPT/HSA complexes is in progress, but these data have not
yet appeared in the literature. Fluorescence spectroscopy stud-
ies of Burke et al. [5^7] demonstrated that carboxylate CPT
binds to a hydrophobic binding pocket on HSA. Aside from
hydrophobic binding, ionic interactions between carboxylate
CPT and the protein [7] were also revealed in these studies.
In recent CD and £uorescence investigations of our group
[8^10] pronounced di¡erences of interactions of lactone, car-
boxylate, and self-aggregated forms of CPT with HSA and
BSA were found. It was shown that HSA binding changes
geometry of CPT's covalent structure resulting from hydro-
phobic contacts of rings A and B of the chromophore with the
protein interior and interactions of carbonyl group of CPT's
ring D with the positively charged amino acid residue of HSA.
Neither heat-denatured HSA nor native BSA exerted binding
of CPT. Analysis of HSA and BSA sequence homology within
the IIA and IIIA principal ligand-binding domains led us to
prediction that the binding site for the CPT chromophore is
located in the subdomain IIA of the HSA structure [10].
In the present report, we employ CD and Raman spec-
troscopy in order to (i) locate the CPT-binding site within
HSA, and (ii) to identify and quantitate conformational
changes of the protein induced by CPT binding. The ¢rst
question is addressed by CD analysis of competitive (with
other ligands occupying IIIA or IIA principal ligand-binding
HSA structural domains) binding of CPT with HSA. The
second problem is resolved by Raman and CD analysis of
CPT-induced changes of protein conformation. CPT-binding
site is proved to be located within the IIA ligand-binding
domain of HSA. Interaction with CPT does not induce sig-
ni¢cant (within ca. 30 peptide bonds) changes in HSA secon-
dary structure, but altered con¢guration of at least two disul-
¢de bridges and transfers a single Trp
214
of HSA (located
within the IIA subdomain) from more hydrophobic (in free
HSA) to hydrophilic (in HSA/CPT complex) environment.
The data suggest that CPT binding induces relative movement
of the protein structural domains. This model seems to be in
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good correlation with homologous multi-domain organisation
of the three-dimensional structure of HSA proposed from the
X-ray structural analysis of the free native protein [11].
2. Materials and methods
2.1. Chemicals
20(S)-CPT, HSA (fatty acid free), AZT and warfarin were pur-
chased from Sigma and used without further puri¢cation. Drug stock
solution of CPT was prepared in DMSO (ACS spectrophotometric
grade, Aldrich) at a concentration 2U10
33
M and stored in the dark
at 370³C. By mixing 1 part of drug stock solution in DMSO with
1 part of PBS bu¡er (pH 10), 1 mM working stock solution of the
carboxylate form of the drug was prepared. 2 mM solution of CPT in
DMSO was used as a stock of a lactone form. Stock solution of HSA
was prepared in PBS bu¡er (pH 7.5) at a concentration 20 mg/ml.
AZT and warfarin were prepared at 100 mM concentrations in PBS
(pH 7.5).
For CD measurements, complex of CPT with HSA was prepared
by mixing of the component's stock solutions in PBS (pH 7.5) to
obtain the ¢nal concentrations 4U10
35
M of CPT and 3 mg/ml (ca.
4.5U10
35
M) of HSA. For Raman spectroscopy, the HSA 20 mg/ml
stock solution and HSA/CPT complexes at the ¢nal concentrations of
18 mg/ml (HSA) and 2U10
34
M (CPT) were used. Only the com-
plexes of HSA with the carboxylate form of CPT were studied by
Raman spectroscopy due to the extremely low solubility of the CPT
lactone form in the aqueous bu¡ers. The ¢nal preparations of com-
plexes studied by both CD and Raman techniques contained 2%
DMSO.
2.2. Circular dichroism and Raman spectroscopy
CD spectra were measured with a Jobin Yvon, Mark III dichro-
graph. Usually CD spectra were recorded using 0.1 mm or 1 cm
quartz cells, in a range 420^185 nm with a 1 or 2 s time constant.
Protein and CPT concentrations were estimated from their molar
absorption coe¤cients in PBS: O
M
278
=39 800 M
31
cm
31
and
O
M
370
=19 900 M
31
cm
31
, respectively. UV-vis spectra were recorded
with a Philips PU8720 UV/vis scanning spectrophotometer. The CD
spectra were scaled to molecular elipticity (vO).
Raman spectra were recorded with a PHO(CODERG) spectrometer
in the frequency range from 300 to 1800 cm
31
. 514.5 nm line of the
Ar-ion Coherent Radiation (model Innova) laser operating with 400
mW power at the sample, was used for excitation. Data accumulation
of 350 independent scans with time averaging was used. The stability
of the protein in the process of laser irradiation was controlled by
analysis of Raman spectra of HSA as a function of time and by
comparison of CD spectra of HSA before and after recording of
the Raman spectra.
The treated Raman spectra of HSA and HSA/CPT complexes were
obtained as follows. First, we recorded the spectra of HSA (in a PBS
solution) and of HSA/CPT complex (in a PBS solution). Then the
spectra of PBS and of the mixture of PBS/DMSO/CPT were recorded.
After subtracting subsequently PBS spectrum from the spectrum of
HSA and PBS/DMSO/CPT spectrum from the spectrum of HSA/CPT
complexes, the spectra of HSA and HSA/CPT presented in the paper
were obtained.
Spectral decomposition in the regions of disul¢de bridges (480^560
cm
31
) and environment-sensitive Trp vibrations (1300^1400 cm
31
)
was performed as described [12]. The quality of decomposition was
checked by comparison of the spectra reconstructed from the decon-
voluted bands with the experimental spectra. An excellent correlation
(with the error 6 2%) was found between theoretical (reconstructed)
and experimental spectra. The procedures were performed using the
CurveFit module of the LabCalc package (Galactic Industries). The
secondary structures of the protein was calculated using RIP (Refer-
ence Intensity Pro¢le) method [12].
2.3. Procedure of competitive binding
Competitive binding CD experiments were employed in order to
locate a CPT-binding site of HSA. Titration of the aqueous bu¡er
solution of a HSA/CPT complex by AZT or warfarin was used in
attempt to replace a HSA-bound CPT by ligands occupying the bind-
ing sites in IIIA (AZT) or IIA (warfarin) domains of the protein. The
¢nal molar ratios of the components in AZT/HSA/CPT and warfarin/
HSA/CPT mixtures were 1000/1/1, i.e. ¢nal concentrations of the
components in reaction mixtures were 2000U10
35
M (warfarin or
AZT), ca. 2U10
35
M (HSA), and ca. 2U10
35
M (CPT).
3. Results and discussion
3.1. Location of the CPT-binding site of HSA
The topology of HSA is created by a repeating series of six
helical subdomains [11]. Consistent with the internal amino-
acid sequence homology, there are three structurally homolo-
gous domains that repeat in the molecule (denoted I, II, and
III). Each domain is formed by two smaller subdomains A
and B, as previously described at high resolution X-ray struc-
ture of HSA (Fig. 1). Altogether, roughly 67% of HSA is
helical, with a remainder in turns and extended polypeptide
[11]. Subdomains A and B possess two identical structural
motives that includes h1^h4 helices for subdomain A and
h7^h10 helices for subdomain B (Fig. 1). In addition to these
motives, subdomain A is supplemented by two additional
short antiparallel helices, h5 and h6, which are tied together
by a pair of disul¢de bridges forming a small disul¢de double
loop. As it was shown from heavy-atom derivative screen and
from preliminary binding studies, the main binding regions on
HSA are located in subdomains IIA and IIIA [11]. The bind-
ing cavity of IIIA is most active and accommodating on HSA.
Many ligands were found to bind there (AZT, digitoxin, ibu-
profen, tryptophan, etc.). Warfarin occupies a single site in
IIA. These observations were based on competitive inhibition
and spectroscopic studies [13^15].
We have recently shown that the interaction of camptothe-
cin with HSA induces pronounced optical activity of the drug,
whereas neither heat-denatured HSA nor native BSA partici-
pated in binding of CPT [8^10]. Analysis of HSA and BSA
sequence homology within the principal ligand-binding do-
mains led us to prediction that the binding site for the CPT
chromophore is located in subdomain IIA. In order to check
this prediction, this paper presents comparative spectroscopic
studies of competitive inhibition of the binding of CPT.
Among the other ligands, AZT is a typical and speci¢c
IIIA-binder, and warfarin-IIA-binder. The binding constants
were found to be ca. 2.5U10
5
M
31
[15]. Neither AZT, nor
warfarin exhibit induced optical activity when in complex with
HSA, whereas CPT/HSA interactions dramatically increase
inherent optical activity of CPT. Hence, competitive binding
of CPT with either AZT or warfarin with HSA may be fruit-
fully studied by means of CD spectroscopy in order to locate
the CPT-binding site of the protein.
FEBS 18841 12-9-97
Fig. 1. Schematic presentation of the HSA structural subdomains
adapted from [11].
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Fig. 2 shows the results of titration of CPT/HSA complex
by warfarin. CD signals of CPT and warfarin are well sepa-
rated. Warfarin exhibits strong CD-band at ca. 309 nm,
whereas free CPT shows only weak contribution in the 300^
320 nm region, but well developed spectrum in the 330^400
nm region (Fig. 2, curve 1). As was shown before [10], inter-
action of CPT with HSA induces strong optical activity of
CPT (Fig. 2, curve 2). Addition of warfarin to the CPT/
HSA complex at 5:1:1 molar ratios of the components shows
simple superposition of CD spectra of free warfarin and CPT/
HSA complex (Fig. 2, curve 3). An increase in warfarin con-
tent up to the 250:1:1 ratio in warfarin/CPT/HSA reaction
mixture (Fig. 2, curve 4) results in a pronounced decrease of a
CD signal of the CPT/HSA complexes, and, ¢nally, induced
optical activity of CPT complexed with HSA totally disap-
pears when the concentration of warfarin reaches 1000:1:1
molar ratio (Fig. 2, curve 5). At these conditions, CPT is
totally replaced from its complex with HSA. The residual
CD signal of CPT corresponds exactly to the optical activity
of the free drug in the aqueous bu¡er solution (Fig. 2, com-
pare curves 1 and 5 in the region 350^400 nm).
As was shown by Burke et al. [7] HSA binds CPT in a
stoichiometry 1:1. From the analysis of the CD spectra of
CPT/HSA complexes at di¡erent ratios of the components,
the binding constant of CPTs carboxylate form with HSA
was calculated to be ca. 1.1þ 0.5U10
7
M
31
. The following
equation was used for calculation of the binding constant:
WU fHSA 3 KCPT 3 K=K
CPT
1 3 Kg
1

1  13K K
CPT
KK
W

31
where [W], [HSA] and [CPT] are the concentrations of war-
farin, HSA and CPT, respectively, K
CPT
and K
W
-binding con-
stants for CPT and warfarin; K-degree of a HSA/CPT com-
plex formation, determined as K= (I3I
F
)/(I
B
3I
F
), where I is
the intensity of the band 341 nm of CPT in a CD spectrum of
reaction mixture, I
F
is the intensity of the band 341 nm in a
CD spectrum of free CPT, and I
B
is the intensity of the band
341 nm for a reaction mixture with 100% CPT bound to HSA
(measured at a 20 mg/ml concentration of HSA).
This calculated value of the CPT^HSA binding constant
(1.1 þ 0.5U10
7
M
31
) is found to be in good agreement with
the data published before (1.2 þ 0.1U10
6
M
31
[7], and
8.0U10
6
M
31
[15]). The binding constant of warfarin to
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Fig. 2. 1,2: CD spectra of CPT's carboxylate form in PBS (1) and in complex with HSA (2). The concentrations of HSA (2U10
35
M) and
CPT (2U10
35
M) in complex correspond to 1:1 molar ratio of components. 3^5: Titration of CPT/HSA complex by warfarin. Warfarin/CPT/
HSA molar ratios were 5:1:1 (3); 250:1:1 (4), and 1000:1:1 (5). The spectra were recorded in a 1 cm cell.
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HSA is known to be ca. 2.5U10
5
M
31
[15], i.e. ca. 50-fold
weaker than that of CPT. So, it seems to be reasonable that
total replacement of CPT by warfarin from CPT/HSA com-
plexes was revealed when the concentration of warfarin was
ca. 1000-fold higher than the concentration of CPT.
We have performed the similar CD measurements but for
competitive binding of AZT and CPT with HSA. Titration by
AZT does not induce any changes in CD spectra of CPT/HSA
complexes up to the 1000:1:1 molar ratio of AZT, CPT and
HSA. Hence, an absence of any changes in CD signals of CPT
bound with HSA in the presence of ca. 1000-fold excess of
AZT undoubtedly demonstrates that these two ligands occupy
di¡erent binding sites of HSA.
Finally, the results of competitive binding of CPT and war-
farin (a ligand which is bound in IIA subdomain of HSA) or
CPT and AZT (a ligand which is bound in IIIA subdomain of
HSA) to HSA show that the CPT-binding site is located with-
in the IIA structural subdomain of the protein.
3.2. HSA structural transformations induced by the CPT
binding
This question is addressed by CD and Raman spectroscopy
analysis of CPT-induced changes in HSA conformation. Fig.
3 shows CD spectra of HSA and CPT/HSA complexes. The
CD spectrum of HSA is typical for K-helical proteins [16]. The
CD spectrum of the CPT/HSA complex was found to be
practically identical (within the experimental error ca. 5%)
to the spectrum of free HSA. So, the CD analysis shows
that interaction with CPT does not induce signi¢cant (within
ca. 30 peptide bonds) changes in the secondary structure of
HSA.
This conclusion is con¢rmed by the Raman spectroscopic
analysis of HSA and HSA/CPT complexes. Fig. 4a shows the
Raman spectrum of HSA. The frequencies and intensities of
Amide I (1654 cm
31
) and Amide III (ca. 1260^1300 cm
31
)
bands of HSA are also typical for an essentially K-helical
protein [17]. We used the methods described in [12] in order
to analyse the Amide I band of HSA. The calculation revealed
ca. 61% of K-helix, 16% of L-sheet and 23% of random coil.
Hence, the secondary structure contents calculated from the
Raman spectrum correspond very well to the data of X-ray
di¡raction [11]. Addition of CPT does not change the frequen-
cies, intensities and shapes of Amide I and Amide III bands of
HSA.
Does the binding of CPT induce local conformational
changes of the protein? Raman spectra of proteins recorded
under non-resonance conditions contain contributions from
various amino acid side chain groups. Some of the side chain
bands provide information of local side chain conformations
or environments [18]. Fig. 4b compares the most informative
parts of the Raman spectra of HSA (up) and CPT/HSA com-
plexes (bottom), corresponding to the regions of S^S stretch-
ing vibrations (480^550 cm
31
), Fermi-resonance Tyr-doublet
(800^860 cm
31
) and microenvironment-sensitive region of Trp
vibrations (1340^1370 cm
31
).
The frequencies of S^S stretching vibrations of disul¢de
bridges of proteins change as a function of internal rotation
about C^S and C^C bonds of the CC^SS^CC moiety. The
vibrations in the region 500^510 cm
31
are assigned to a
gauche^gauche^gauche (g^g^g) conformation, whereas a
gauche^gauche^trans (g^g^t) rotamer gives the band at 515^
525 cm
31
, and a trans^gauche^trans (t^g^t) at 535^545 cm
31
[18]. In the three-dimensional structure of HSA, 17 cysteines
form disul¢de linkages [11]. Calculations of the ratios of in-
tegrated intensities of the bands in the 480^550 cm
31
region
corresponding to di¡erent rotamers in the Raman spectrum of
HSA (Fig. 4b, top) show, that six disul¢de bridges of HSA are
in g^g^t, seven in g^g^g, and four other in t^g^t conforma-
tion. Addition of CPT leads to changes in relative integrated
intensities of S^S bands in the Raman spectrum (Fig. 4b,
bottom). Two disul¢de bridges change their local conforma-
tion. Seven disul¢de bonds are found to be in g^g^t, ¢ve in g^
g^g, and ¢ve in t^g^t con¢gurations. The data suggest CPT-
induced transformation of two disul¢de bridges of CPT from
g^g^g to g^g^t and to t^g^t conformation.
The spectral region 800^860 cm
31
contains bands at about
830 and 850 cm
31
(so-called `Fermi-resonance Tyr-doublet'),
which are extremely sensitive to hydrogen bonding of the
phenolic OH-groups [19]. The intensity ratio I
850
/I
830
re£ects
`exposed' and/or `buried' tyrosines. A ratio of about 2.5 in-
dicates that the hydroxyl group is an acceptor of strong hy-
drogen bonding from a positive donor group [19]. This is the
case of HSA (Fig. 4b, top): the ratio of bands within the
observed Tyr-doublet shows that the main fraction of tyro-
sines of the protein is H-bonded with more positive donor
groups. Addition of CPT (Fig. 4b, bottom) does not induce
any modi¢cations in the I
850
/I
830
ratio.
There is a unique Trp
214
in the HSA molecule. The intensity
of the 1360 cm
31
band is a marker of hydrophobicity of
microenvironment of the indole ring. Its intensity grows as
hydrophobicity of the environment increases [20]. The Raman
spectrum shows that Trp
214
of HSA is at least partially in
hydrophobic environment but it becomes totally hydrophilic
when going from free HSA to CPT/HSA complex (Fig. 4b).
Finally, the CD and Raman spectra show that the interac-
tion of CPT with HSA does not modify (within the 5% ex-
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Fig. 3. CD spectra of HSA (1) and CPT/HSA complex (2) at the
1:1 drug/protein molar ratio. The spectra were measured in PBS,
pH 7.4, at 25³C. Concentration of the components: 4U10
35
M.
The spectrum was recorded in a 0.1 mm cell.
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perimental error 9 ca. 30 peptide groups) the secondary struc-
ture of the protein, but changes con¢guration of at least two
disul¢de bridges. Interaction with CPT transfers a single
Trp
214
of HSA (located within the IIA subdomain) from the
more hydrophobic to the hydrophilic environment.
HSA has a greater a¤nity for small, negatively charged
hydrophobic molecules [15]. In this regard it is notable that
HSA is the principal carrier of numerous pharmaceuticals in
the blood which have otherwise limited solubility. If the drugs
of CPT family, potent topo I inhibitors, are concerned, it is
HSA that makes a signi¢cant impact on the drug stability [4^
10] and may play a role of delivery machine in the blood. This
paper shows that CPT binds within the IIA structural subdo-
main of HSA. It is known that both warfarin (occupying IIA)
and triiodobenzoic acid (typical equipotent binder within IIA
and IIIA subdomains of HSA) are located in that part of the
cavity created by a smaller disul¢de double loop (h5 and h6,
Fig. 1), within the region of inter-domain connections [11]. So,
it seems to be logical to suggest that the two disul¢de bonds
within the smaller disul¢de double loop (connecting helices
h4^h5 and h5^h6) change their conformation upon the bind-
ing of CPT. This transfer of the more compact g^g^g to the
more extended g^g^t and t^g^t con¢gurations should obvi-
ously lead to the relative movement of the protein structural
domains. This relative rotation of domains may explain a
transfer of the single Trp
214
, located within the bottom half
of h4 helice of the IIA structural subdomain (Fig. 1), from the
more hydrophobic to the hydrophilic microenvironment.
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